Vikrant Jagadeesan, J Hunter Mehaffey, Mohammed A Kawsara, Dhaval Chauhan, J W Awori Hayanga, Christopher E Mascio, J Scott Rankin, Ramesh Daggubati, Vinay Badhwar
{"title":"Transcatheter vs Surgical Aortic Valve Replacement in Medicare Beneficiaries with Aortic Stenosis and Coronary Artery Disease.","authors":"Vikrant Jagadeesan, J Hunter Mehaffey, Mohammed A Kawsara, Dhaval Chauhan, J W Awori Hayanga, Christopher E Mascio, J Scott Rankin, Ramesh Daggubati, Vinay Badhwar","doi":"10.1016/j.athoracsur.2024.12.016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>As percutaneous therapeutic options expand, the optimal management of severe aortic stenosis (AS) and concomitant coronary artery disease (CAD) is being questioned between coronary artery bypass grafting and surgical aortic valve replacement (CABG+SAVR) versus percutaneous coronary intervention and transcatheter aortic valve replacement (PCI+TAVR). We sought to compare perioperative and longitudinal risk-adjusted outcomes between patients undergoing CABG+SAVR versus PCI+TAVR.</p><p><strong>Methods: </strong>Using the United States Centers for Medicare and Medicaid Services inpatient claims database, we evaluated all patient age 65 and older with AS and CAD undergoing CABG+SAVR or PCI+TAVR (2018-2022). Comorbidities and frailty were accounted for using validated metrics with doubly robust risk-adjustment using inverse probability weighting, multilevel regression, and competing-risk time to event analyses. The primary endpoint was 5-year composite of stroke, myocardial infarction (MI), valve reintervention and/or death.</p><p><strong>Results: </strong>A total of 37,822 patients formed the study cohort (PCI+TAVR, n=17,413; CABG+AVR, n=20,409). Accounting for age, comorbidities, frailty, and number of vessels revascularized, PCI+TAVR was associated with lower procedural mortality (1.1% vs 3.6%, OR 0.29, p < 0.001), but higher vascular complications (OR 6.02, p < 0.001) and new permanent pacemaker (OR 1.92, p < 0.001). However, the longitudinal 5-year primary endpoint favored CABG+SAVR (20.4% vs 14.2%, OR 1.44, p < 0.001). Subgroup analyses demonstrated a benefit in the use of arterial conduit in CABG+SAVR in patients with single vessel CAD.</p><p><strong>Conclusions: </strong>Among Medicare beneficiaries with severe AS and CAD, CABG+SAVR was associated with higher procedural mortality than PCI+TAVR but lower 5-year risk-adjusted stroke, MI, valve reintervention, and death.</p>","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Thoracic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.athoracsur.2024.12.016","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: As percutaneous therapeutic options expand, the optimal management of severe aortic stenosis (AS) and concomitant coronary artery disease (CAD) is being questioned between coronary artery bypass grafting and surgical aortic valve replacement (CABG+SAVR) versus percutaneous coronary intervention and transcatheter aortic valve replacement (PCI+TAVR). We sought to compare perioperative and longitudinal risk-adjusted outcomes between patients undergoing CABG+SAVR versus PCI+TAVR.
Methods: Using the United States Centers for Medicare and Medicaid Services inpatient claims database, we evaluated all patient age 65 and older with AS and CAD undergoing CABG+SAVR or PCI+TAVR (2018-2022). Comorbidities and frailty were accounted for using validated metrics with doubly robust risk-adjustment using inverse probability weighting, multilevel regression, and competing-risk time to event analyses. The primary endpoint was 5-year composite of stroke, myocardial infarction (MI), valve reintervention and/or death.
Results: A total of 37,822 patients formed the study cohort (PCI+TAVR, n=17,413; CABG+AVR, n=20,409). Accounting for age, comorbidities, frailty, and number of vessels revascularized, PCI+TAVR was associated with lower procedural mortality (1.1% vs 3.6%, OR 0.29, p < 0.001), but higher vascular complications (OR 6.02, p < 0.001) and new permanent pacemaker (OR 1.92, p < 0.001). However, the longitudinal 5-year primary endpoint favored CABG+SAVR (20.4% vs 14.2%, OR 1.44, p < 0.001). Subgroup analyses demonstrated a benefit in the use of arterial conduit in CABG+SAVR in patients with single vessel CAD.
Conclusions: Among Medicare beneficiaries with severe AS and CAD, CABG+SAVR was associated with higher procedural mortality than PCI+TAVR but lower 5-year risk-adjusted stroke, MI, valve reintervention, and death.
期刊介绍:
The mission of The Annals of Thoracic Surgery is to promote scholarship in cardiothoracic surgery patient care, clinical practice, research, education, and policy. As the official journal of two of the largest American associations in its specialty, this leading monthly enjoys outstanding editorial leadership and maintains rigorous selection standards.
The Annals of Thoracic Surgery features:
• Full-length original articles on clinical advances, current surgical methods, and controversial topics and techniques
• New Technology articles
• Case reports
• "How-to-do-it" features
• Reviews of current literature
• Supplements on symposia
• Commentary pieces and correspondence
• CME
• Online-only case reports, "how-to-do-its", and images in cardiothoracic surgery.
An authoritative, clinically oriented, comprehensive resource, The Annals of Thoracic Surgery is committed to providing a place for all thoracic surgeons to relate experiences which will help improve patient care.